Scientific expertise from validation to market

Science-led companies eighteen to thirty-six months from a capital raise, strategic transaction or listing.

Investors and acquirers evaluating a life sciences or medtech asset where the science is outside their own competence.

Research institutes and corporates with a validated platform seeking a clear route to market.

Biodvance is not a contract research organization. It does not run studies.

All client work is delivered by Dr Bart De Wever, PhD. No subcontractors.

The name on the proposal and the work in the deliverable are the same person.

Engagements begin with a conversation.